Literature DB >> 10505486

Two cases of olanzapine-induced reversible neutropenia.

A Steinwachs1, R Grohmann, F Pedrosa, E Rüther, I Schwerdtner.   

Abstract

Olanzapine is a tricyclic neuroleptic agent that due to structural similarities was expected to be a safe alternative to clozapine, which has a 0.5-2% risk of agranulocytosis. So far, only rare cases of leukocytopenia and thrombocytopenia have become known. In the association, "Drug Safety in Psychiatry", which is made up of 25 German psychiatric hospitals, two cases of olanzapine-induced neutropenia occurred in patients with chronic schizophrenia. The adverse drug reaction was noticed 17 days after the first intake of olanzapine in case 1 and more than 5 months after the first intake in case 2. In the second case, a reexposure to olanzapine caused the neutrophil cells to decrease again. There were no clinical signs of an infection, and the blood cell counts increased immediately to normal ranges after discontinuation of olanzapine. No special treatment was necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10505486     DOI: 10.1055/s-2007-979222

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

1.  Thrombocytopenia and fatality associated with olanzapine.

Authors:  Juan Antonio Carrillo; José Antonio González; Guillermo Gervasini; Rosa López; María Angeles Fernández; Guillermo Martín Núñez
Journal:  Eur J Clin Pharmacol       Date:  2004-05-19       Impact factor: 2.953

2.  A case of neutropenia and thrombocytopenia shortly after initiaing olanzapine.

Authors:  Aditi Mehta; John Sanitato
Journal:  Psychiatry (Edgmont)       Date:  2005-09

Review 3.  Switching between second-generation antipsychotics: why and how?

Authors:  Monika Edlinger; Susanne Baumgartner; Nadja Eltanaihi-Furtmüller; Martina Hummer; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Olanzapine-Induced Neutropenia.

Authors:  Kirti Malhotra; Priscilla Vu; Danielle H Wang; Hank Lai; Lawrence R Faziola
Journal:  Ment Illn       Date:  2015-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.